A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye (RESTA)

Laboratoire Chauvin

Status: Completed

Conditions: Dry Eye

Treatments: Device: Vismed Multi eye drops; Device: CBL-102 eye drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT03368404

2017-A01099-44

Details and patient eligibility

About

This is a multicenter, randomized, parallel group, investigator-masked, non-inferiority study. Approximately 84 subjects will be randomized in a 1:1 ratio.The primary objectives of this investigation are to show that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day. The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye at Visit 4 (Day 28 ± 3 days) in ocular surface fluorescein staining score.

Enrollment: 92 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects of legal age (at least 18) and able to read, understand, and provide written voluntary informed consent on the Ethics Committee (EC) approved Informed Consent Form

2. Subjects able and willing to comply with all treatment and follow-up and study procedures

3. Subjects who have been using tear substitutes for at least 2.5 months prior to inclusion, and who will use multidose preservative-free ART (Aqualarm® U.P. povidone 2% eye drops in 10 mL bottles) up to 6 times a day for at least 2 weeks immediately prior to randomization

4. Subjects with a score ≥ 1 for at least 2 out of the 7 following symptoms (rated 0 to 4): sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light

5. Subjects with at least 1 eye with the following signs of keratoconjunctivitis sicca :

   • "Tear break-up time of 10 sec (mean of 3 measurements) at both screening visit and inclusion visit"
   • "Total ocular surface staining score ≥ 4 and ≤ 9 at both screening visit and inclusion visit. This assessment combines corneal, nasal and temporal bulbar conjunctival fluorescein staining, each graded 0-5 according to the Oxford Scheme"

6. Subjects who have a decimal visual acuity (VA) with habitual correction equal to or better than 0.1 (Monoyer chart) in both eyes

7. Subjects with no systemic treatment or who are receiving stable systemic treatment (unchanged for 1 month or longer)

8. For Female subjects, they must fall into 1 of the following categories:

   • "Post-menopausal"
   • "Surgically sterile"
   • "Using birth control method throughout the duration of the study"

9. For Female subjects who are of childbearing potential (i.e. who are not post-menopausal or not surgically sterile), they must have a negative urine pregnancy test result at screening

Exclusion criteria

1. Subjects with severe blepharitis

2. Subjects who have severe ocular dryness accompanied by 1 of the following:

   • "Lid abnormality (except mild or moderate blepharitis)"
   • "Corneal disease"
   • "Ocular surface metaplasia"
   • "Filamentary keratitis"
   • "Corneal neovascularization"

3. Subjects who currently wear contact lenses or have worn contact lenses within 90 days prior to study start

4. Subjects who have received ocular surgery, including laser surgery, in either eye within 180 days prior to study start

5. Subjects with a history of ocular trauma, non-dry eye ocular inflammation, or ocular infection within 90 days prior to study start

6. Subjects with a history of ocular allergic disease or ocular herpes within 1 year prior to study start

7. Subjects with a history of any inflammatory ulcerative keratitis, recurrent corneal erosion, or uveitis

8. Subjects with known hypersensitivity or contraindications to any of the ingredients in the test or comparator products or ART

9. Subjects with initiation of, or changes to, concomitant medication that could affect dry eye within 30 days prior to Visit 1 (Screening) or with planned initiation or changes of such medications during the study

10. Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start

11. Subjects expected to receive ocular therapy during the study

12. Subjects treated with topical ocular steroidal or non-steroidal anti-inflammatory medication within 30 days prior to study start

13. Subjects expected to receive ocular therapy with immunosuppressants (eg, cyclosporine) during the study or who have used ocular immunosuppressants within 90 days prior to study start

14. Subjects who have received occlusion therapy with non resorbable lacrimal or punctum plugs within 90 days prior to study start or subjects with resorbable plugs

15. Subjects who have received or who are planned to receive therapy such as LipiFlow® or BlephEx®

16. Females who are breastfeeding

17. Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

92 participants in 2 patient groups

CBL-102 eye drops

Experimental group

Description:

CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides

Treatment:

Device: CBL-102 eye drops

Vismed Multi eye drops

Active Comparator group

Description:

CE marked medical device, tear substitute containing 0.18% sodium hyaluronate

Treatment:

Device: Vismed Multi eye drops